Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials

被引：0

作者：

Craig Leonardi

Kristian Reich

Peter Foley

Hideshi Torii

Sascha Gerdes

Lyn Guenther

Melinda Gooderham

Laura K. Ferris

Christopher E. M. Griffiths

Hany ElMaraghy

Heidi Crane

Himanshu Patel

Russel Burge

Gaia Gallo

David Shrom

Ann Leung

Chen-Yen Lin

Kim Papp

机构：

[1] Central Dermatology,Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing

[2] University Medical Center Hamburg-Eppendorf,St. Vincent’s Hospital Melbourne and Probity Medical Research, Skin Health Institute

[3] Skinflammation® Center,Division of Dermatology

[4] The University of Melbourne,Psoriasis

[5] Tokyo Yamate Medical Center,Center at the Department of Dermatology

[6] University Medical Center Schleswig-Holstein,Dermatology Centre, Salford Royal Hospital

[7] Guenther Dermatology Research Centre,undefined

[8] SkiN Centre for Dermatology and Probity Medical Research,undefined

[9] University of Pittsburgh Medical Center,undefined

[10] University of Manchester,undefined

[11] Eli Lilly and Company,undefined

[12] Lilly Corporate Center,undefined

[13] Syneos Health,undefined

[14] K. Papp Clinical Research and Probity Medical Research Inc.,undefined

来源：

Dermatology and Therapy | 2020年 / 10卷

关键词：

Ixekizumab; Long-term efficacy; Long-term safety; Maintain; Psoriasis; Quality of life; 5 years;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：431 / 447

页数：16

共 50 条

[1] Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials
Leonardi, Craig
Reich, Kristian
Foley, Peter
Torii, Hideshi
Gerdes, Sascha
Guenther, Lyn
Gooderham, Melinda
Ferris, Laura K.
Griffiths, Christopher E. M.
ElMaraghy, Hany
Crane, Heidi
Patel, Himanshu
Burge, Russel
Gallo, Gaia
Shrom, David
Leung, Ann
Lin, Chen-Yen
Papp, Kim
DERMATOLOGY AND THERAPY, 2020, 10 (03) : 431 - 447
[2] Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3)
Reich, Kristian
Leonardi, Craig
Lebwohl, Mark
Kerdel, Francisco
Okubo, Yukari
Romiti, Ricardo
Goldblum, Orin
Dennehy, Ellen B.
Kerr, Lisa
Sofen, Howard
JOURNAL OF DERMATOLOGICAL TREATMENT, 2017, 28 (04) : 282 - 287
[3] Maintenance of Efficacy Results from UNCOVER-1: A Phase 3 Trial of Ixekizumab for Moderate-to-Severe Plaque Psoriasis
Leonardi, C.
Leutz, A.
Blauvelt, A.
Langley, R. G.
Luger, T.
Ohtsuki, M.
Cameron, G. S.
Erickson, J.
Zhao, F.
Shrom, D. S.
Braun, D.
Osuntokun, O. O.
Heffernan, M.
Nickoloff, B. J.
Gordon, K.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 : 4 - 4
[4] Maintenance of efficacy results from UNCOVER-1: A phase 3 trial of ixekizumab for moderate-to-severe plaque psoriasis
Leonardi, Craig
Blauvelt, Andrew
Langley, Richard
Luger, Thomas
Ohtsuki, Mamitaro
Cameron, Gregory S.
Braun, Daniel
Erickson, Janelle
Zhao, Fangyi
Shrorn, David S.
Osuntokun, Olawale O.
Heffernan, Michael P.
Nickoloff, Brian
Gordon, Kenneth
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S16 - S16
[5] Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3
Egeberg, Alexander
Wu, Jashin J.
Korman, Neil
Solomon, James A.
Goldblum, Orin
Zhao, Fangyi
Mallbris, Lotus
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (01) : 104 - +
[6] Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3)
Menter, A.
Warren, R. B.
Langley, R. G.
Merola, J. F.
Kerr, L. N.
Dennehy, E. B.
Shrom, D.
Amato, D.
Okubo, Y.
Reich, K.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (10) : 1686 - 1692
[7] Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
Griffiths, Christopher E. M.
Reich, Kristian
Lebwohl, Mark
van de Kerkhof, Peter
Paul, Carle
Menter, Alan
Cameron, Gregory S.
Erickson, Janelle
Zhang, Lu
Secrest, Roberta J.
Ball, Susan
Braun, Daniel K.
Osuntokun, Olawale O.
Heffernan, Michael P.
Nickoloff, Brian J.
Papp, Kim
LANCET, 2015, 386 (9993): : 541 - 551
[8] Long-term efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis sustained for three years: Results of a randomized controlled phase 3 study (UNCOVER-3)
Leonardi, Cathy L.
Maari, Catherine
Philipp, Sandra
Crowley, Jeffrey
Zhang, Lu
Ball, Susan
Mallbris, Lotus
Gonzalez, Pablo
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB180 - AB180
[9] Efficacy of ixekizumab therapy: integrated analysis of 3 double-blind, controlled trials UNCOVER-1, UNCOVER-2, UNCOVER-3
Papp, K.
Leonardi, C.
Blauvelt, A.
Korman, N.
Ohtsuki, M.
Reich, K.
Mallbris, L.
Ball, S.
Erickson, J.
Griffiths, C. E.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (09) : S170 - S170
[10] Number needed to treat associated with ixekizumab and etanercept from UNCOVER-2 and UNCOVER-3 Phase III trials in the treatment of moderate-to-severe psoriasis
Foster, S.
Zhu, B.
Burge, R.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (05) : S27 - S27

← 1 2 3 4 5 →